Berkeley Biologics Draws Warning Letter for Unapproved Bone Matrix Products

Richmond, Calif.-based Berkeley Biologics failed to file BLAs for several bone matrix products distributed to medical facilities nationwide and lacked proper screening for tissue donors, among other serious lapses cited in an FDA Warning Letter.
Source: Drug Industry Daily